^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    clonoSEQ

    Company:
    Adaptive Biotech
    12d
    NIRVANA: Non-invasive MRD Assessment in Multiple Myeloma (clinicaltrials.gov)
    P=N/A, N=36, Completed, Rajshekhar Chakraborty, MD | Recruiting --> Completed | N=88 --> 36 | Trial completion date: Jun 2026 --> Dec 2025
    Trial completion • Enrollment change • Trial completion date • Liquid biopsy • Minimal residual disease
    |
    clonoSEQ
    12d
    Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL (clinicaltrials.gov)
    P3, N=466, Not yet recruiting, Alliance for Clinical Trials in Oncology
    New P3 trial
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    Chr t(11;14)
    |
    clonoSEQ
    |
    Brukinsa (zanubrutinib) • sonrotoclax (BGB-11417)
    13d
    Study of Epcoritamab as a Consolidation Therapy in CLL/SLL (clinicaltrials.gov)
    P2, N=22, Recruiting, Zulfa Omer | Not yet recruiting --> Recruiting
    Enrollment open
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • SF3B1 (Splicing Factor 3b Subunit 1) • CD79B (CD79b Molecule) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • BIRC3 (Baculoviral IAP repeat containing 3) • CD5 (CD5 Molecule) • POT1 (Protection of telomeres 1) • H1-4 (H1.4 Linker Histone, Cluster Member) • NFKBIE (NFKB Inhibitor Epsilon) • ZMYM3 (Zinc Finger MYM-Type Containing 3) • CHD2 (Chromodomain Helicase DNA Binding Protein 2) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    Chr del(11q)
    |
    clonoSEQ
    |
    Gazyva (obinutuzumab) • Epkinly (epcoritamab-bysp)
    14d
    ESR-23-22182: Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL (clinicaltrials.gov)
    P2, N=62, Recruiting, Zulfa Omer | Not yet recruiting --> Recruiting | Initiation date: Jun 2025 --> Dec 2025
    Enrollment open • Trial initiation date
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • SF3B1 (Splicing Factor 3b Subunit 1) • CD79B (CD79b Molecule) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • BIRC3 (Baculoviral IAP repeat containing 3) • CD5 (CD5 Molecule) • POT1 (Protection of telomeres 1) • H1-4 (H1.4 Linker Histone, Cluster Member) • NFKBIE (NFKB Inhibitor Epsilon) • ZMYM3 (Zinc Finger MYM-Type Containing 3) • CHD2 (Chromodomain Helicase DNA Binding Protein 2) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    Chr del(11q)
    |
    clonoSEQ
    |
    Venclexta (venetoclax) • Calquence (acalabrutinib)
    27d
    Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, University of Alberta
    New P2 trial
    |
    clonoSEQ
    |
    Iclusig (ponatinib)
    28d
    MagnetisMM-7: Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant (clinicaltrials.gov)
    P3, N=811, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    clonoSEQ
    |
    lenalidomide • Elrexfio (elranatamab-bcmm)
    1m
    A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=283, Active, not recruiting, AbbVie | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    clonoSEQ
    |
    lenalidomide • Darzalex (daratumumab) • dexamethasone • pomalidomide • etentamig intravenous (ABBV-383 IV)
    1m
    NIRVANA: Non-invasive MRD Assessment in Multiple Myeloma (clinicaltrials.gov)
    P=N/A, N=88, Recruiting, Rajshekhar Chakraborty, MD | Trial completion date: Nov 2025 --> Jun 2026 | Trial primary completion date: Nov 2025 --> Feb 2026
    Trial completion date • Trial primary completion date • Liquid biopsy • Minimal residual disease
    |
    clonoSEQ
    1m
    A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, M.D. Anderson Cancer Center
    New P1 trial
    |
    clonoSEQ
    |
    Revuforj (revumenib)
    1m
    Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation (clinicaltrials.gov)
    P2, N=20, Recruiting, City of Hope Medical Center | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Sep 2025 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    clonoSEQ
    |
    Opdivo (nivolumab) • Imbruvica (ibrutinib) • cyclophosphamide • Breyanzi (lisocabtagene maraleucel) • fludarabine IV
    2ms
    ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma (clinicaltrials.gov)
    P2, N=160, Not yet recruiting, Massachusetts General Hospital
    New P2 trial
    |
    clonoSEQ
    |
    lenalidomide • bortezomib • Elrexfio (elranatamab-bcmm) • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • dexamethasone injection
    2ms
    MRD-driven Initial Therapy of Acalabrutinib and Lenalidomide plus Rituximab (ALR) or Obinutuzumab (ALO) for Mantle Cell Lymphoma. (PubMed, Blood Adv)
    Longitudinal cfDNA analysis in ALR revealed clonal evolution during response and progression. This safe and active regimen is feasible as a time-limited initial therapy for MCL patients and warrants further evaluation in response-adapted strategy.
    Journal
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    clonoSEQ
    |
    Rituxan (rituximab) • lenalidomide • Gazyva (obinutuzumab) • Calquence (acalabrutinib)